SuzanneReimFanningDO

Oncology • Greenville, SC

Greenville Health Sysytem Cancer Institute

Join to view full profile

Dr. Fanning is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fanning's full profile

Already have an account?

Office
65 International Dr
Greenville, SC 29615
Phone+1 864-987-7000

Fax+1 864-987-7020

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007
Lehigh Valley Health NetworkResidency, Internal Medicine, 2001 - 2004
Philadelphia College of Osteopathic MedicineClass of 2001

Certifications & Licensure

SC State License 2007 - 2025
OH State License 2004 - 2009
PA State License 2001 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia Start of enrollment: 1999 Apr 01
Active, not recruiting
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2010 Sep 01
Completed
Phase 2
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab Start of enrollment: 2010 May 01
Completed
Phase 2
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma Start of enrollment: 2015 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

30 citations
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single‐arm, phase 2 study
Michael Wang, Leslie Popplewell, Robert H. Collins, Jane N. Winter, Andre Goy
British Journal of Haematology. 2014-05-01
32 citations
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors.
Shahrukh K. Hashmi, Stephanie J. Lee, Bipin N. Savani, Linda J. Burns, John R. Wingard
Biology of Blood and Marrow Transplantation. 2018-06-01
26 citations
Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Luciano J. Costa, Suzanne R. Fanning, Joe Stephenson, Lawrence B. Afrin, Emily Kistner-Griffin
Leukemia & Lymphoma. 2015-03-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member